These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15064342)

  • 21. Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells.
    Kishi Y; Ohta S; Kasuya N; Sakita SY; Ashikaga T; Isobe M
    J Hypertens; 2003 Jul; 21(7):1347-53. PubMed ID: 12817183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis.
    Collet JP; Montalescot G; Lesty C; Soria J; Mishal Z; Thomas D; Soria C
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):142-8. PubMed ID: 11145946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ectonucleoside triphosphate diphosphohydrolase 1/CD39, localized in neurons of human and porcine heart, modulates ATP-induced norepinephrine exocytosis.
    Machida T; Heerdt PM; Reid AC; Schäfer U; Silver RB; Broekman MJ; Marcus AJ; Levi R
    J Pharmacol Exp Ther; 2005 May; 313(2):570-7. PubMed ID: 15647328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties.
    Haller CA; Cui W; Wen J; Robson SC; Chaikof EL
    J Vasc Surg; 2006 Apr; 43(4):816-23. PubMed ID: 16616242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transmembrane domains confer different substrate specificities and adenosine diphosphate hydrolysis mechanisms on CD39, CD39L1, and chimeras.
    Grinthal A; Guidotti G
    Biochemistry; 2002 Feb; 41(6):1947-56. PubMed ID: 11827541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection.
    Imai M; Takigami K; Guckelberger O; Enjyoji K; Smith RN; Lin Y; Csizmadia E; Sévigny J; Rosenberg RD; Bach FH; Robson SC
    Mol Med; 1999 Nov; 5(11):743-52. PubMed ID: 10656876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
    Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
    Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet glycoprotein IIb/IIIa receptor antagonist (abciximab) inhibited platelet activation and promoted skin flap survival after ischemia/reperfusion injury.
    Kuo YR; Jeng SF; Wang FS; Huang HC; Wei FC; Yang KD
    J Surg Res; 2002 Sep; 107(1):50-5. PubMed ID: 12384064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ratio of ADP- to ATP-ectonucleotidase activity is reduced in patients with coronary artery disease.
    El-Omar MM; Islam N; Broekman MJ; Drosopoulos JH; Roa DC; Lorin JD; Sedlis SP; Olson KE; Pulte ED; Marcus AJ
    Thromb Res; 2005; 116(3):199-206. PubMed ID: 15935828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro effects of the glycoprotein IIb/IIIa receptor antagonists abciximab and eptifibatide on platelet aggregation in healthy cats.
    Magee AN; Hogan DF; Sederquist KA; Durham JA
    Am J Vet Res; 2014 Mar; 75(3):309-12. PubMed ID: 24564318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombotic effects of abciximab.
    Hayes R; Chesebro JH; Fuster V; Dangas G; Fallon JT; Sharma SK; Coller BS; Badimon L; Marmur JD; Badimon JJ
    Am J Cardiol; 2000 May; 85(10):1167-72. PubMed ID: 10801995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.
    Gold HK; Garabedian HD; Dinsmore RE; Guerrero LJ; Cigarroa JE; Palacios IF; Leinbach RC
    Circulation; 1997 Apr; 95(7):1755-9. PubMed ID: 9107158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.
    Graff J; Andries D; Elsner M; Westrup D; Bassus S; Franz N; Klinkhardt U; Harder S
    Br J Clin Pharmacol; 2001 Jun; 51(6):577-82. PubMed ID: 11422017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.
    Nakada MT; Montgomery MO; Nedelman MA; Guerrero JL; Cohen SA; Barnathan ES; Jordan RE
    J Vasc Interv Radiol; 2004 Feb; 15(2 Pt 1):169-76. PubMed ID: 14963184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
    Kleiman NS; Grazeiadei N; Maresh K; Taylor RJ; Frederick B; Lance ET; Effron MB; Jordan RE; Mascelli MA
    Am Heart J; 2000 Sep; 140(3):492-501. PubMed ID: 10966553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.
    Enjyoji K; Sévigny J; Lin Y; Frenette PS; Christie PD; Esch JS; Imai M; Edelberg JM; Rayburn H; Lech M; Beeler DL; Csizmadia E; Wagner DD; Robson SC; Rosenberg RD
    Nat Med; 1999 Sep; 5(9):1010-7. PubMed ID: 10470077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved blood compatibility of a stent graft by combining heparin coating and abciximab.
    Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
    Thromb Res; 2005; 115(3):245-53. PubMed ID: 15617748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.